Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more
Sareum Hldgs Plc - Asset Resilience Ratio
Sareum Hldgs Plc (SAR) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2021)
This chart shows how Sareum Hldgs Plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sareum Hldgs Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | £0.00 | 0% |
| Short-term Investments | £1.00 | 0.0% |
| Total Liquid Assets | £1.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sareum Hldgs Plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sareum Hldgs Plc Industry Peers by Asset Resilience Ratio
Compare Sareum Hldgs Plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Sareum Hldgs Plc (2014–2021)
The table below shows the annual Asset Resilience Ratio data for Sareum Hldgs Plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 87.24% | £2.69 Million | £3.08 Million | -2.39pp |
| 2020-06-30 | 89.63% | £1.79 Million | £2.00 Million | +89.63pp |
| 2019-06-30 | 0.00% | £1.00 | £1.24 Million | -75.37pp |
| 2018-06-30 | 75.37% | £1.37 Million | £1.82 Million | -16.45pp |
| 2017-06-30 | 91.82% | £2.30 Million | £2.50 Million | +80.63pp |
| 2014-06-30 | 11.18% | £200.00K | £1.79 Million | -- |